<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02834559</url>
  </required_header>
  <id_info>
    <org_study_id>uni-koeln-1782</org_study_id>
    <secondary_id>2015-004731-12</secondary_id>
    <nct_id>NCT02834559</nct_id>
  </id_info>
  <brief_title>Prophylactic Intravitreal 5-Fluorouracil and Heparin to Prevent PVR in High-risk Patients With Retinal Detachment.</brief_title>
  <acronym>PRIVENT</acronym>
  <official_title>Prophylactic Intravitreal 5-Fluorouracil and Heparin to Prevent PVR in High-risk Patients With Retinal Detachment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Köln</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Clinical Trials Centre Cologne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pharmacy of the University Hospital Erlangen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Medical Statistics, Informatics and Epidemiology (IMSIE)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitätsklinikum Köln</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the effectiveness of a simple treatment to prevent proliferative&#xD;
      vitreoretinopathy (PVR).&#xD;
&#xD;
      Intraoperative intravitreal 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) is&#xD;
      used as a prophylactic therapy in high-risk patients with primary rhegmatogenous retinal&#xD;
      detachment (RRD). Our major motivation is to reduce the incidence of PVR in the group that&#xD;
      receives the trial drug.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Proliferative vitreoretinopathy (PVR) is a common cause for postoperative failure after&#xD;
      vitreoretinal surgery for primary RRD. There is no standard-therapy to prevent PVR. Several&#xD;
      attempts using chemotherapeutic agents have been undertaken to prevent this&#xD;
      proliferation-process, but none of these was introduced into routine clinical practice.&#xD;
&#xD;
      Until recently, it has been challenging to identify patients with high risk for postoperative&#xD;
      PVR formation. This is especially important, because in this trial treatment with the trial&#xD;
      drug will be restricted to patients at high risk for PVR only.&#xD;
&#xD;
      Patients are assigned to the following treatment arms (1:1):&#xD;
&#xD;
      (A) Intraoperative adjuvant application of 5-fluorouracil (5-FU) and low molecular weight&#xD;
      heparin (LMWH) via intraocular infusion during routine pars plana vitrectomy (PPV) in&#xD;
      high-risk patients for proliferative vitreoretinopathy (PVR) with primary rhegmatogenous&#xD;
      retinal detachment (RRD).&#xD;
&#xD;
      Versus:&#xD;
&#xD;
      (B) Routinely used intraocular infusion with balanced salt solution (BSS) during routine PPV.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proliferative Vitreoretinopathy (PVR) grade CP (posterior - full thickness retinal folds in clock hours) 1 or higher [yes/no]</measure>
    <time_frame>within 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PVR grade CP 1 or higher [yes/no]</measure>
    <time_frame>within 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PVR grade CA (anterior - full thickness retinal folds in clock hours) 1 or higher [yes/no]</measure>
    <time_frame>within 6 weeks and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of PVR (PVR grade CA 1-12, PVR grade CP 1-12 (in clock hours))</measure>
    <time_frame>within 6 weeks and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Corrected Visual Acuity (BCVA) measured by ETDRS charts</measure>
    <time_frame>within 6 weeks and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal reattachment after primary intervention [yes/no]</measure>
    <time_frame>within 6 weeks and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of retinal re-detachments and if present due to PVR [yes/no]</measure>
    <time_frame>within 6 weeks and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and extent of surgical procedures necessary to achieve retinal reattachment</measure>
    <time_frame>within 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of at least one drug-related adverse event that affects the study eye [yes/no]</measure>
    <time_frame>within 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">326</enrollment>
  <condition>Rhegmatogenous Retinal Detachment</condition>
  <condition>High-risk for Proliferative Vitreoretinopathy (PVR)</condition>
  <arm_group>
    <arm_group_label>Adjuvant therapy with 5-FU and LMWH</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intraoperative adjuvant application of 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) via intraocular infusion during routine pars plana vitrectomy (PPV) in high-risk patients for proliferative vitreoretinopathy (PVR) with primary rhegmatogenous retinal detachment (RRD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Routinely used intraocular infusion with balanced salt solution (BSS) during routine pars plana vitrectomy (PPV) in high-risk patients for proliferative vitreoretinopathy (PVR) with primary rhegmatogenous retinal detachment (RRD).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil and low molecular weight heparin</intervention_name>
    <description>Intraoperative adjuvant application of 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) via intraocular infusion during routine pars plana vitrectomy (PPV).</description>
    <arm_group_label>Adjuvant therapy with 5-FU and LMWH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Routinely used intraocular infusion with balanced salt solution (BSS) during routine pars plana vitrectomy (PPV).</description>
    <arm_group_label>Standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Primary rhegmatogenous retinal detachment (&lt; 4 weeks) in study eye&#xD;
&#xD;
          2. Scheduled for pars plana vitrectomy for retinal detachment repair without combined&#xD;
             cataract surgery in study eye&#xD;
&#xD;
          3. Elevated protein levels in anterior chamber fluid (laser-flare value ≥ 15.0 pc/ms) in&#xD;
             study eye&#xD;
&#xD;
          4. Female or male patient ≥ 18 years of age&#xD;
&#xD;
          5. Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Retinal detachment lasting &gt; 4 weeks in study eye&#xD;
&#xD;
          2. Traumatic retinal detachment in study eye&#xD;
&#xD;
          3. Giant retinal tears in study eye (size &gt; 3 clock hours)&#xD;
&#xD;
          4. Visual pre-existing PVR grade C in study eye&#xD;
&#xD;
          5. Retinal dystrophies in study eye&#xD;
&#xD;
          6. Scheduled for combined pars plana vitrectomy and cataract surgery for retinal&#xD;
             detachment repair in study eye&#xD;
&#xD;
          7. Chronic inflammatory conditions in study eye&#xD;
&#xD;
          8. Active retinal vascular disease in study eye&#xD;
&#xD;
          9. Proliferative diabetic retinopathy in study eye&#xD;
&#xD;
         10. Manifest uveitis in study eye&#xD;
&#xD;
         11. Endophthalmitis in study eye&#xD;
&#xD;
         12. Perforating and non-perforating trauma in study eye&#xD;
&#xD;
         13. Malignant intraocular tumor in study eye&#xD;
&#xD;
         14. Aphakia in study eye&#xD;
&#xD;
         15. Uncontrolled glaucoma or ocular hypertension in study eye (intraocular pressure ≥ 30&#xD;
             mmHg despite IOP lowering therapy)&#xD;
&#xD;
         16. Previous intraocular surgery except uncomplicated cataract surgery with posterior&#xD;
             chamber lens implantation in study eye&#xD;
&#xD;
         17. Cataract surgery in study eye ≤ 3 months ago&#xD;
&#xD;
         18. Previous retinal procedures (laserpexy, cryopexy, intravitreal gas-injection,&#xD;
             anti-VEGF or corticosteroid-injection) in study eye ≤ 6 months&#xD;
&#xD;
         19. Other uncontrolled ophthalmologic disorders&#xD;
&#xD;
         20. Single eyed patients (BCVA of fellow eye &gt; 1.0 log MAR, &lt; 0.1 decimal, &lt; 1/10 tenth,&#xD;
             or &lt; 6/60 Snellen fraction [m])&#xD;
&#xD;
         21. Evidence or history of alcohol, medication or drug dependency within the last 12&#xD;
             months.&#xD;
&#xD;
         22. Evidence or history (within the last 12 months) of neurotic personality, psychiatric&#xD;
             illness that requires or required treatment, epilepsy or suicide risk.&#xD;
&#xD;
         23. Systemic disorders not compatible with adjuvant application of 5-FU and LMWH via&#xD;
             intraocular infusion, or not compatible with the local or general anesthesia&#xD;
&#xD;
         24. Any therapy with immunosuppressant or chemotherapy ≤ 3 months and during the trial&#xD;
             period&#xD;
&#xD;
         25. Participation in another trial of IMPs or devices parallel to, or less than 3 months&#xD;
             before screening, or previous participation in this trial.&#xD;
&#xD;
         26. Known to or suspected of not being able to comply with the protocol.&#xD;
&#xD;
         27. Inability to understand the rationale of this trial or the study aim&#xD;
&#xD;
         28. Any dependency of the patient to the Investigator or the trial site, e.g. employees&#xD;
             with direct involvement in the proposed trial or in other trials under the direction&#xD;
             of this Investigator or trial site, as well as family members of the employees or the&#xD;
             Investigator.&#xD;
&#xD;
         29. Positive urine pregnancy test, pregnancy or breastfeeding mother.&#xD;
&#xD;
         30. Women of child bearing potential without satisfactory contraception, i.e. hormonal&#xD;
             contraceptives for at least 14 days before trial enrolment, IUD, double barrier (women&#xD;
             of child bearing age must be counselled about the use of adequate contraception).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Friederike Schaub, PD. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Ophthalmology, University of Cologne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Augenklinik Uniklinik Freiburg</name>
      <address>
        <city>Freiburg</city>
        <state>BW</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>STZ eyetrial am Department für Augenheilkunde</name>
      <address>
        <city>Tübingen</city>
        <state>BW</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Augenheilkunde Uniklinik Hamburg Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <state>HH</state>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augenklinik Uniklinik Bonn</name>
      <address>
        <city>Bonn</city>
        <state>NRW</state>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäts-Augenklinik Düsseldorf</name>
      <address>
        <city>Dusseldorf</city>
        <state>NRW</state>
        <zip>40255</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augenklinik der Universität zu Köln</name>
      <address>
        <city>Koln</city>
        <state>NRW</state>
        <zip>50931</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augenärzte am St. Franziskushospital Münster Augenklinik</name>
      <address>
        <city>Munster</city>
        <state>NRW</state>
        <zip>48145</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Knappschaftskrankenhaus Sulzbach Augenklinik Sulzbach</name>
      <address>
        <city>Sulzbach</city>
        <state>Saarbrücken</state>
        <zip>66280</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik Leipzig Klinik und Poliklinik für Augenheilkunde</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsaugenklinik Göttingen</name>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsaugenklinik Kiel</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augenklinik TU München</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsaugenklinik Regensburg</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 12, 2016</study_first_submitted>
  <study_first_submitted_qc>July 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2016</study_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Detachment</mesh_term>
    <mesh_term>Vitreoretinopathy, Proliferative</mesh_term>
    <mesh_term>Dissociative Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Tinzaparin</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

